Methods of inhibitng gastric secretion with prostaglandin derivatives
AssigneeMiles Inc.
InventorsHarold C. Kluender, Warren D. Woessner, William G. Biddlecom
Life of this patent
Estimating the term…
Abstract
A therapeutic method for inhibiting gastric secretion in an individual for whom such therapy is indicated is disclosed. The method comprises administering to such an individual an effective inhibitory amount of certain derivatives of 15-deoxy-16-hydroxy-prostaglandin E.sub.1 esters.
Claims4
A therapeutic method for inhibiting gastric secretion in an individual to whom such therapy is indicated, comprising:
- administering to the individual an effective gastric inhibiting amount of methyl 11.alpha.,16RS-dihydroxy-16,20-methano-9-oxoprost-13E-en-1-oate.
A therapeutic method for inhibiting gastric secretion in an individual to whom such therapy is indicated, comprising:
- administering to the individual an effective gastric inhibiting amount of methyl 11.alpha.,16RS-dihydroxy-16,18-methano-17,20-methano-9-oxoprosta-13E,19-di en-1-oate.
A therapeutic method for inhibiting gastric secretion in an individual to whom such therapy is indicated, comprising:
- administering to the individual an effective gastric inhibiting amount of methyl 11.alpha.,16RS-dihydroxy-16,18-methano-17,20-methano-9-oxoprost-13E-en-1-o ate.
A therapeutic method for inhibiting gastric secretion in an individual to whom such therapy is indicated, comprising:
- administering to the individual an effective gastric inhibiting amount of methyl 11.alpha.,16RS-dihydroxy-16,20-methano-17,20-methano-9-oxoprost-13E-en-1-o ate.
Dependencies are inferred from the claim text.